For patients with locally advanced rectal cancer (LARC), it is unclear whether neoadjuvant chemoradiotherapy-induced pathologic complete response (pCR) individuals would further benefit from adjuvant chemotherapy (ACT).
The pCR individuals who received different ACT cycles were paired by propensity score matching. Overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were calculated by Kaplan–Meier and log-rank test.
In total, 1041 pCR individuals were identified from 5567 LARC cases. Specifically, 303 pCR cases had no ACT treatment, and 738 pCR patients received fluoropyrimidine-based ACT (median, 4 cycles) treatment. After 1:3 propensity score matching, 297 cases without ACT treatment were matched to 712 cases who received ACT treatment. Kaplan–Meier analysis showed that pCR individuals treated with or without ACT had the similar 3-year outcome (OS, DFS, LRFS and DMFS) (all P > 0.05). Moreover, the pCR patients received different ACT cycle(s) (0 vs. 1–4 cycles, 0 vs. ≥5 cycles) had comparable 3-year OS, DFS, LRFS and DMFS (all P > 0.05). In stratified analysis, ACT treatment did not improve 3-year survival (OS, DFS, LRFS and DMFS) for the baseline high-risk (cT3–4/cN1–2) subgroup patients (all P > 0.05).
ACT, which did not improve survival, is unnecessary to neoadjuvant treatment-induced pCR LARC patients.
Subscribe to Journal
Get full journal access for 1 year
only $20.79 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
NCCN. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (version 2.2019). https://doi.org/10.6004/jnccn.2009.0057.
Sauer, R., Becker, H., Hohenberger, W., Rodel, C., Wittekind, C., Fietkau, R. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731–1740 (2004).
Sebag-Montefiore, D., Stephens, R. J., Steele, R., Monson, J., Grieve, R., Khanna, S. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373, 811–820 (2009).
Collette, L., Bosset, J. F., den Dulk, M., Nguyen, F., Mineur, L., Maingon, P. et al. Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J. Clin. Oncol. 25, 4379–4386 (2007).
Maas, M., Nelemans, P. J., Valentini, V., Das, P., Rodel, C., Kuo, L. J. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 11, 835–844 (2010).
Park, I. J., You, Y. N., Agarwal, A., Skibber, J. M., Rodriguez-Bigas, M. A., Eng, C. et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J. Clin. Oncol. 30, 1770–1776 (2012).
Garcia-Aguilar, J., Chow, O. S., Smith, D. D., Marcet, J. E., Cataldo, P. A., Varma, M. G. et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 16, 957–966 (2015).
Cercek, A., Roxburgh, C. S. D., Strombom, P., Smith, J. J., Temple, L. K. F., Nash, G. M. et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 4, e180071 (2018).
Zhang, J. W., Cai, Y., Xie, X. Y., Hu, H. B., Ling, J. Y., Wu, Z. H., et al. Nomogram for predicting pathological complete response and tumor downstaging in patients with locally advanced rectal cancer on the basis of a randomized clinical trial. Gastroenterol. Rep. (Oxf.) 8, 234–241 (2020).
Fokas, E., Strobel, P., Fietkau, R., Ghadimi, M., Liersch, T., Grabenbauer, G. G. et al. Tumor regression grading after preoperative chemoradiotherapy as a prognostic factor and individual-level surrogate for disease-free survival in rectal cancer. J. Natl Cancer Inst. 109, 12 (2017).
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322, 352–358 (1990).
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H. 3rd, Carrato, A. et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352, 2696–2704 (2005).
Andre, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109–3116 (2009).
Quasar Collaborative, G., Gray, R., Barnwell, J., McConkey, C., Hills, R. K., Williams, N. S. et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370, 2020–2029 (2007).
Bosset, J. F., Calais, G., Mineur, L., Maingon, P., Stojanovic-Rundic, S., Bensadoun, R. J. et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 15, 184–190 (2014).
Sainato, A., Cernusco Luna Nunzia, V., Valentini, V., De Paoli, A., Maurizi, E. R., Lupattelli, M. et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother. Oncol. 113, 223–229 (2014).
Breugom, A. J., van Gijn, W., Muller, E. W., Berglund, A., van den Broek, C. B., Fokstuen, T. et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann. Oncol. 26, 696–701 (2015).
Carvalho, C. & Glynne-Jones, R. Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncol. 18, e354–e363 (2017).
Bujko, K., Glynne-Jones, R. & Bujko, M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann. Oncol. 21, 1743–1750 (2010).
Shahab, D., Gabriel, E., Attwood, K., Ma, W. W., Francescutti, V., Nurkin, S. et al. Adjuvant chemotherapy is associated with improved overall survival in locally advanced rectal cancer after achievement of a pathologic complete response to chemoradiation. Clin. Colorectal Cancer 16, 300–307 (2017).
Xu, Z., Mohile, S. G., Tejani, M. A., Becerra, A. Z., Probst, C. P., Aquina, C. T. et al. Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: an NCDB analysis. Cancer 123, 52–61 (2017).
Turner, M. C., Keenan, J. E., Rushing, C. N., Gulack, B. C., Nussbaum, D. P., Benrashid, E. et al. Adjuvant chemotherapy improves survival following resection of locally advanced rectal cancer with pathologic complete response. J. Gastrointest. Surg. 23, 1614–1622 (2019).
Dossa, F., Acuna, S. A., Rickles, A. S., Berho, M., Wexner, S. D., Quereshy, F. A. et al. Association between adjuvant chemotherapy and overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection. JAMA Oncol. 4, 930–937 (2018).
Tomasello, G., Ghidini, M. & Petrelli, F. Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery. Eur. J. Cancer 108, 97–99 (2019).
Ma, B., Ren, Y., Chen, Y., Lian, B., Jiang, P., Li, Y. et al. Is adjuvant chemotherapy necessary for locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery? A systematic review and meta-analysis. Int. J. Colorectal Dis. 34, 113–121 (2019).
Breugom, A. J., Swets, M., Bosset, J. F., Collette, L., Sainato, A., Cionini, L. et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 16, 200–207 (2015).
Capirci, C., Valentini, V., Cionini, L., De Paoli, A., Rodel, C., Glynne-Jones, R. et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int. J. Radiat. Oncol. Biol. Phys. 72, 99–107 (2008).
Beets, G. L. & Glimelius, B. L. Adjuvant chemotherapy for rectal cancer still controversial. Lancet Oncol. 15, 130–131 (2014).
Polanco, P. M., Mokdad, A. A., Zhu, H., Choti, M. A. & Huerta, S. Association of adjuvant chemotherapy with overall survival in patients with rectal cancer and pathologic complete response following neoadjuvant chemotherapy and resection. JAMA Oncol. 4, 938–943 (2018).
Chang, G. J. Is there validity in propensity score-matched estimates of adjuvant chemotherapy effects for patients with rectal cancer? JAMA Oncol. 4, 921–923 (2018).
Fokas, E., Liersch, T., Fietkau, R., Hohenberger, W., Beissbarth, T., Hess, C. et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J. Clin. Oncol. 32, 1554–1562 (2014).
Rodel, C., Martus, P., Papadoupolos, T., Fuzesi, L., Klimpfinger, M., Fietkau, R. et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J. Clin. Oncol. 23, 8688–8696 (2005).
Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rodel, C., Cervantes, A. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl. 4), iv263 (2018).
Rödel, C., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D. et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 16, 979–989 (2015).
Ethics approval and consent to participate
This study was approved by the central ethics committee of the Sixth Affiliated Hospital, Sun Yat-sen University in accordance with the Declaration of Helsinki (No. 2019ZSLYEC-136). The written consent of patients was waived by the ethical committee of the Sixth Affiliated Hospital, Sun Yat-sen University.
Consent to publish
The datasets used during the current study are available from the corresponding author on reasonable request.
The authors declare no competing interests.
This study was supported by International Centre for Genetic Engineering and Biotechnology Research Grant (No. CRP/CHN16-04_EC) and Natural Science Foundation of China (Nos. 81872188 and 81703080).
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
He, F., Ju, H., Ding, Y. et al. Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection. Br J Cancer 123, 1244–1252 (2020). https://doi.org/10.1038/s41416-020-0989-1